Salamanca’s first serious outbreak of bronchiolitis came weeks earlier than usual, but they did so with an important “statistic”: The youngest patient admitted is only 10 months old.
According to the Pediatric Services of Salamanca Hospital, there are currently Five children were admitted to the ward with bronchiolitis, and one child was admitted to the pediatric intensive care unit..
What’s striking about these numbers is that they’re not babies of a few weeks or months who are most likely to develop bronchiolitis, but rather most children over one year old. In fact, one of the patients admitted (approximately two years old) had a nursing sister who did receive niselumab and was perfectly healthy at home.
Pediatricians think it’s “a bit hasty” to draw conclusions because ‘Our case only lasted a few weeks’but out of an abundance of caution, they do see promising signs that a new drug against bronchiolitis – niselumab – is working.
The first fact is that most children admit Bronchiolitis due to rhinovirus It’s the virus that causes the common cold, but it’s not respiratory syncytial virus (RSV), which the new drug can immunize against.
The second encouraging fact is Children admitted are “older”. In October, Castile and Leon began using the RSV “vaccine” (which is not a vaccine itself) on children born between March 1, 2023, and March 31, 2024. This margin means newborns will currently be vaccinated. 0 months and 10 months. It seems no coincidence that the children admitted to the Salamanca hospital are all over ten months old.
«Last year’s bronchiolitis season was terrible. It is not prudent to predict this year at this time, but niselumab may have an impact,” they said.
Newborns are very receptive to this “vaccine” People who are already receiving treatment in the hospital. Dr. Javier Pellegrini confirmed a few weeks ago that the primary care data are also very good. On the other hand, neonatal influenza vaccination is not well accepted in this population.